Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks
Study Infliximab (n) Non-infliximab (n) Total (n) Odds ratio Appau et al. [8] 60 329 389 2.93 (1.63–5.27) Canedo et al. [11] 65 160 225 1.19 (0.58–2.42) Kasparek et al….